Review Reports
- Irina Ianache 1,2,‡,
- Roxana Radoi 2 and
- Cristiana Oprea 1,2,*,‡
- et al.
Reviewer 1: Anonymous Reviewer 2: Tian-hao Zhang
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThis article examines the effect of a doravirine-based salvage ART regimen combined with dolutegravir or bictegravir in HT-PWH. The study found that this salvage regimen was effective in adherent THE-PWH with extensive ART histories. The study is well designed and executed, and the present manuscript is well written. The following are the specific comments to further strengthen the manuscript,
Specific comments,
- In the abstract background section, the text can be improved for better clarity. Method looks good.
- In abstract, results and conclusions look good.
- The salvage ART regimens seem to be controlling HIV; this study is still ongoing, and we can expect more data in the future from this study.
- If there is any evidence of immune reconstitution after the salvage ART regimens, it would be an interesting addition to the manuscript and would help the audience better understand the effect.
Author Response
Comment 1: In the abstract background section, the text can be improved for better clarity. Method looks good.
Response: Management of heavily treatment-experienced people living with HIV (HTE-PWH) remains challenging due to long antiretroviral therapy (ART) exposure in those with lack of adherence and/or toxicities leading to limited treatment options.
Comment 3: The salvage ART regimens seem to be controlling HIV; this study is still ongoing, and we can expect more data in the future from this study.
Response: This study will be continued and we will monitor our patients to assess efficacy, durability and tolerability of the regimen
Comment 4 If there is any evidence of immune reconstitution after the salvage ART regimens, it would be an interesting addition to the manuscript and would help the audience better understand the effect.
Response 4: We didn't observe this aspect but we will continue to monitor our patients and we will update the data base. Half of the patients enrolled until now where well-controlled at switch. PLH who needed salvage ART had a median CD4 cell count of 269/μL, not at IRIS risk.
Reviewer 2 Report
Comments and Suggestions for AuthorsThe manuscript entitled Optimizing salvage ART: real-world outcomes of doravirine plus DTG or BIC in heavily treatment-experienced persons living with HIV describes treatment outcomes in a highly vulnerable, historically unique population. The manuscript provides important insights on regime shift in resource limited settings. However, the description and interpretation of the manuscript could be improved. Thus, I recommend a minor revision of the manuscript.
- Half of the patients were virologically suppressed while shifting to a simplified regime, without genotyping the virus drug resistance. The authors should have an ethical approval from the Hospital’s Ethics Committee. The authors should also clearly state the contingency plan for the regime shift. This includes how is the viral load and CD4 count monitored in these people, when to determine if the regime shift is failing and should shift to the original regime, as well as other necessary details.
- The authors should explain the inclusion and exclusion criteria of the cohort. The Victor Babies Hospital hosts a large number of people living with HIV. The authors could state why they include these 69 individuals in the cohort. In the 12-month follow-up, there are 48 patients with viral load measurement. The authors could also state why some of the patients are excluded from the study (E.g. loss to follow-up, transfers, death, discontinuation, or missing labs).
- The authors used 40 copies/mL as the detection limit (Method Line 95). But in Figure 1, they used 50 copies/mL as the detection limit. This should be consistent.
- To better assess the results of the regime shift, the authors should report not only the viral load, but also CD4 count and other clinically relevant outcomes (E.g. clinical adverse events, opportunistic infections and AIDS events, mortality, or regime discontinuation). So, the readers could have a better understanding of the actual effect of simplified regime.
- Three different salvage regimes are used in this study. The authors could do a better job explaining the reason of adapting different regime for different patients. Currently there is only explanation for 3TC/DTG + DOR (NRTI toxicities).
Author Response
Comment 1: Half of the patients were virologically suppressed while shifting to a simplified regime, without genotyping the virus drug resistance. The authors should have an ethical approval from the Hospital’s Ethics Committee. The authors should also clearly state the contingency plan for the regime shift. This includes how is the viral load and CD4 count monitored in these people, when to determine if the regime shift is failing and should shift to the original regime, as well as other necessary details.
Response:
We thank the reviewer for raising this important point. The study was approved by the Hospital Ethics Committee (approval number, date, and code were provided to the Editors). Although the study was initially conceived as prospective because we intend to continue longitudinal follow-up of this cohort, we agree that, at the time of publication, it is more appropriately classified as an observational real-world data study. Treatment switches were not protocol-driven but were decided on an individual basis by the treating HIV clinicians according to routine clinical practice. All people living with HIV (PLH) followed in our department are routinely monitored every 6–12 months. Regimen changes were implemented in cases of virologic failure or clinically relevant toxicities (e.g., renal or neurological adverse events). Importantly, more than half of the patients in our cohort originated from the pediatric HIV program and were heavily treatment-experienced, with prior exposure to multiple antiretroviral classes (NRTIs, NNRTIs, PIs, and in some cases first-generation INSTIs) and a history of therapeutic failures and/or documented resistance mutations. Because of the possibility of archived resistance, clinicians considered it unsafe to use single-tablet regimens containing only an INSTI or doravirine in these individuals. Additionally, in a few subjects, HIV viral load was low and insufficient for successful amplification. We have revised the manuscript accordingly to clarify the study design and the real-world nature of treatment decisions. (see line 23 and line 81in the manuscript)
Comment 2: The authors should explain the inclusion and exclusion criteria of the cohort. The Victor Babies Hospital hosts a large number of people living with HIV. The authors could state why they include these 69 individuals in the cohort. In the 12-month follow-up, there are 48 patients with viral load measurement. The authors could also state why some of the patients are excluded from the study (E.g. loss to follow-up, transfers, death, discontinuation, or missing labs).
Response:
All patients who initiated salvage antiretroviral therapy (ART) regimens during the study period were included based on data collected from medical records. Viral load measurements at 12 months were unavailable for some of the 69 patients because they did not attend scheduled testing within the at time frame. Nevertheless, these individuals remained in active clinical follow-up and continued their prescribed ART. Subsequent viral load assessments confirmed undetectable HIV RNA levels in these patients.
Comment 3: The authors used 40 copies/mL as the detection limit (Method Line 95). But in Figure 1, they used 50 copies/mL as the detection limit. This should be consistent.
Response:
Indeed, the detection limit of the assay used is 40 copies/mL. However, we reported a threshold of 50 copies/mL because this cut-off is commonly used in data presentation ensuring consistency and comparability with published literature.
The methods section has been updated to clarify this point, (line 103-105)
Comment 4: To better assess the results of the regime shift, the authors should report not only the viral load, but also CD4 count and other clinically relevant outcomes (E.g. clinical adverse events, opportunistic infections and AIDS events, mortality, or regime discontinuation). So, the readers could have a better understanding of the actual effect of simplified regime.
Response: This is an important observation! No opportunistic infections or other AIDS-related events were observed during the study period; however, these data were not included in the current manuscript. We plan to continue the follow-up of this cohort, and future analyses will include longer-term monitoring of patients, incorporating CD4 cell counts and any clinically relevant events.
Comment 5: Three different salvage regimes are used in this study. The authors could do a better job explaining the reason of adapting different regime for different patients. Currently there is only explanation for 3TC/DTG + DOR (NRTI toxicities).
Reesponse: The choice of regimen for each patient was made on an individualized basis, according to their antiretroviral therapy (ART) history. In some cases, treatment switches were necessary to avoid toxicities, which is why NRTI toxicity was provided as an example. In instances of virologic failure or other adverse effects, the new regimen was carefully selected based on each patient’s treatment history and the potential presence of archived resistance mutations.